X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs IPCA LABS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA IPCA LABS AUROBINDO PHARMA/
IPCA LABS
 
P/E (TTM) x 14.2 25.6 55.3% View Chart
P/BV x 2.9 4.3 66.1% View Chart
Dividend Yield % 0.4 0.1 403.5%  

Financials

 AUROBINDO PHARMA   IPCA LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
IPCA LABS
Mar-18
AUROBINDO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs809695 116.3%   
Low Rs504400 126.0%   
Sales per share (Unadj.) Rs281.1260.2 108.0%  
Earnings per share (Unadj.) Rs41.419.0 218.0%  
Cash flow per share (Unadj.) Rs50.933.1 153.9%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.40.2 208.6%  
Book value per share (Unadj.) Rs199.4213.0 93.6%  
Shares outstanding (eoy) m585.88126.20 464.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.1 111.0%   
Avg P/E ratio x15.928.9 55.0%  
P/CF ratio (eoy) x12.916.6 77.9%  
Price / Book Value ratio x3.32.6 128.1%  
Dividend payout %6.05.3 114.7%   
Avg Mkt Cap Rs m384,63069,120 556.5%   
No. of employees `00017.313.3 130.8%   
Total wages/salary Rs m21,3087,359 289.6%   
Avg. sales/employee Rs Th9,500.72,477.4 383.5%   
Avg. wages/employee Rs Th1,229.4555.2 221.4%   
Avg. net profit/employee Rs Th1,397.9180.6 773.9%   
INCOME DATA
Net Sales Rs m164,66632,836 501.5%  
Other income Rs m1,020418 244.0%   
Total revenues Rs m165,68633,254 498.2%   
Gross profit Rs m37,7184,505 837.3%  
Depreciation Rs m5,5801,777 313.9%   
Interest Rs m777240 323.6%   
Profit before tax Rs m32,3802,905 1,114.5%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183511 1,601.0%   
Profit after tax Rs m24,2292,394 1,012.0%  
Gross profit margin %22.913.7 167.0%  
Effective tax rate %25.317.6 143.6%   
Net profit margin %14.77.3 201.8%  
BALANCE SHEET DATA
Current assets Rs m121,87819,455 626.5%   
Current liabilities Rs m86,80610,076 861.5%   
Net working cap to sales %21.328.6 74.6%  
Current ratio x1.41.9 72.7%  
Inventory Days Days13098 132.7%  
Debtors Days Days6867 102.1%  
Net fixed assets Rs m81,03720,260 400.0%   
Share capital Rs m586252 232.1%   
"Free" reserves Rs m116,21826,633 436.4%   
Net worth Rs m116,80426,886 434.4%   
Long term debt Rs m4,5122,340 192.8%   
Total assets Rs m211,05241,173 512.6%  
Interest coverage x42.713.1 325.8%   
Debt to equity ratio x00.1 44.4%  
Sales to assets ratio x0.80.8 97.8%   
Return on assets %11.86.4 185.2%  
Return on equity %20.78.9 232.9%  
Return on capital %27.410.8 254.2%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m80,72715,642 516.1%   
Fx outflow Rs m34,7004,884 710.5%   
Net fx Rs m46,02710,759 427.8%   
CASH FLOW
From Operations Rs m19,5483,411 573.0%  
From Investments Rs m-19,570-1,354 1,445.3%  
From Financial Activity Rs m8,642-1,304 -662.6%  
Net Cashflow Rs m8,922753 1,184.6%  

Share Holding

Indian Promoters % 54.1 45.9 117.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.4 69.7%  
FIIs % 27.7 25.3 109.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.4 58.6%  
Shareholders   69,601 36,892 188.7%  
Pledged promoter(s) holding % 8.6 2.1 400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy and Automobiles Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.9% while the Hang Seng is up 0.2%.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 23, 2019 10:59 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS